

ITL Ranked 16th Most Innovative Company in Australia

ITL, the innovative diversified medical technology company and owner of MyHealthTest, is proud to announce it has been ranked the 16th Most Innovative Company in Australia at the AFR Top 50 Most Innovative Awards.

The AFR Most Innovative Companies list ranks the most innovative organisations in Australia, and is the only national, cross-industry list of its kind.

Bill Mobbs, ITL Chairman commented “This is a fantastic achievement. This is justification of ITL’s decision earlier in the year to transform the business by accelerating the development of innovative patented products and to steer MyHealthTest to reach its exciting commercial potential.”

“Congratulations to all the staff at ITL and we look forward to announcing further innovations in the future”

Key Innovations



In 2015 ITL acquired MyHealthTest (MHT), a direct to consumer pathology testing service that identified the need for more accessible pathology testing for chronic diseases. ITL saw MHT as being an extremely innovative and disruptive service that is unique in Australia.

MHT’s test kits are ordered online or purchased in pharmacy, and a finger-prick blood sample is taken at home. The sample is returned to the lab via regular mail and results are delivered online, and results can be shared with a doctor. This is in contrast to the traditional system requiring a doctor visit, a pathology request and a visit to a pathology centre before results are received at the 2nd doctor visit; this is costly in time and co-payments to the healthcare system.

ITL Limited ABN 16 088 212 088
Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL’s patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL’s wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.

Australian Securities Exchange

Code: ITD

Ordinary Shares

95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Company Secretary & Chief Financial Officer
---------------	--

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles	Walbrook IR
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.com.au

MHT's first test is the HbA1c test for the diagnosis and monitoring of diabetes. Diabetes was targeted as one of the fastest growing conditions worldwide, with significant impacts on the individual and the healthcare system.

MHT has received support from State based diabetes associations and been accepted into the NRMA Jumpstart program and HCF's Catalyst program, providing potential exposure to their enormous membership bases. New products are targeted for frequently monitored chronic conditions such as heart disease, prostate and thyroid conditions.



ITL BioMedical is an innovation lead company that has been built on identifying urgent needs in the medical industry and providing unique solutions that now make up an extensive global IP portfolio.

ITL BioMedical designed and patented a medical device that saves the lives of patients needing platelet donations, called SampLok Sampling Kit (SSK). SSK is used in the testing of platelet blood cells intended to be used in transfusions for a range of medical conditions. The unique patented design averts risk of needle stick injury to the laboratory technician, delivers a measured amount of platelets for testing and ensures that during the testing process no bacteria have the opportunity to contaminate the donation.

SSK has been patented and received regulatory clearance in several countries and is seeing growing sales in the USA, UK, Taiwan and New Zealand.

ITL BioMedical launched 11 new products in the last financial year and is on target to do the same this financial year. In addition to these, 7 provisional patents, 3 PCT and 4 national phase cases were lodged, whilst another 2 were granted that took ITL's total owned live patent cases to 49.

Bill Mobbs continued "ITL is a proven innovator and we are focused on continuing to innovate and leverage off our ongoing successes."

"After launching less than 2 years ago MHT has already been accepted by some of the highest qualified industry participants for its diabetes test and we look forward to announcing further tests for chronic diseases in the coming 6 to 12 months."